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Abstract 
The structural factors of antimycin A molecule required for inhibitory action were studied using newly synthesized antimycin A 
derivatives with bovine heart submitochondrial p rticles, in order to probe the interaction between antimycin A and its binding site. In 
particular, we focused upon the roles of the amide bond bridge, which connects the salicylic acid and dilactone ring moieties, and the 
3-formylamino group in the salicylic acid moiety. The lack of formation of an intramolecular hydrogen-bond between phenolic OH and 
amide carbonyl groups resulted in a remarkable oss of the activity (by four orders of magnitude), indicating that this hydrogen-bond is 
essential for the inhibition. This result suggested that both the phenolic OH and the carbonyl groups form a hydrogen-bond with some 
residues at a fixed conformation. In addition, the inhibitory potency was remarkably decreased by N-methylation of the amide bond 
moiety, indicating that the NH group might function in hydrogen-bond interaction with the binding site. The N-methylation of 
3-formylamino group also resulted in a decrease in the activity, probably due to a loss of the rotational freedom of this functional group. 
Molecular orbital calculation studies with respect to the conformation ofthe 3-formylamino group indicated that his group takes an active 
conformation when the formyl carbonyl projects to the opposite side of the phenolic OH group. Based upon a series of structure-activity 
studies of synthetic antimycin A analogues, we propose atentative model for antimycin A binding in its binding cavity. 
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I. Introduction 
The antibiotic antimycin A is a natural product of 
various species of Streptomyces. This compound inhibits 
cytochrome bc 1 complex activity by blocking electron 
transfer from the heine b H center to ubiquinone [1]. For 
the development of mechanistic oncepts and structural 
aspects of cytochrome bc I complex, antimycin A has been 
widely used [1-6]. Information about the antimycin A 
binding domain of cytochrome b has been obtained using 
mitochondrial mutants resistant o this inhibitor [4,7-9], 
whereas the portion of antimycin A molecule that interacts 
with the mutated positions remains unknown. To gain 
insight into the interaction between antimycin A and its 
binding domain, the structural factors of antimycin A 
essential for the inhibition should be identified. 
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The structure of natural antimycin A is shown in Fig. 1, 
taking antimycin A 3 as an example. The benzene and 
dilactone-ring planes locate on and above the page plane in 
Fig. 1, respectively. Using a synthetic stereoisomer of 
natural antimycin A 3 ((-)-antimycin A3, in which the 
spatial position of the benzene ring plane relative to that of 
the dilactone ring is opposite to the position for natural 
antimycin A3) , we showed that the configuration of an- 
timycin A is important for its inhibitory action [10]. This 
strongly suggested that the shape of whole antimycin A 
molecule is strictly recognized by the binding site. How- 
ever, the natural dilactone ring moiety itself is not essential 
for the activity; that is, flexible and hydrophobic structures 
such as dialkyl L-glutamate and substituted diphenyl ether 
are favorable substituents for the dilactone ring [11]. It is 
therefore likely that antimycin A binding to a Qi center is 
primarily governed by a specific interaction between the 
salicylic acid moiety and the binding site. In fact, it has 
been shown that antimycin A-resistant yeast mitochondrial 
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mutants are specifically resistant o the inhibition by syn- 
thetic antimycin A analogues that possess a natural sali- 
cylic acid moiety but not a natural dilactone ring [12]. 
Furthermore, we demonstrated that both the 3-for- 
mylamino group in its proper conformation and the pheno- 
lic OH group are essential for the inhibitory action [13]. 
This study indicated that these two substituents are strictly 
recognized by the binding cavity, although the 3-for- 
mylamino group is thought to be not essential for the 
activity [14,15], 
Antimycin A consists of 3-formylaminosalicylic a id 
linked via an amide bond to a dilactone ring moiety. The 
roles of both ring moieties have been elucidated [10,11,13], 
whereas the roles of the amide bond moiety remain un- 
known. In this study, we synthesized three new antimycin 
A derivatives (compounds B, D and E, Fig. 1) by modify- 
ing the distance between the benzene ring and the amide 
bond or by N-methylation. The substituent pattern on the 
benzene ring was set as that of natural antimycin A 
(3-formylamino salicyl). The portion corresponding to the 
dilactone ring was replaced by suitable mimetic structures 
[11,13], since total synthesis of the natural dilactone ring is 
still difficult despite recent progress [16,17]. Their in- 
hibitory potencies of ubiquinol-cytochrome c oxidoreduc- 
tase activity were compared with those of the correspond- 
ing control compounds (A and C, Fig. 1) using bovine 
heart submitochondrial particles. We also performed 
molecular orbital calculation studies on the conformation 
of the 3-formylamino group, which is important for the 
inhibitory action [13], to investigate its active conforma- 
tion. Based upon a series of structure-activity studies of 
synthetic antimycin A analogues, we proposed a tentative 
model of antimycin A binding in the receptor cavity. 
2. Experimental procedures 
2.1. Materials 
Antimycin A and cytochrome c (horse heart) were 
purchased from Sigma and 2,3-dimethoxy-5-methyl-6-n- 
decyl-l,4-benzoquinol (DBH) was prepared as described 
[18]. Compounds A and C are the same as those used in 
the previous studies [11,13]. Other reagents were of the 
purest grade commercially available. 
2.2. Synthesis 
Compound B. The precursor of compound B was 
synthesized by condensation of di-n-octyl L-glutamate with 
2-hydroxy-3-nitrophenylacetic ac d, which was prepared 
from commercially available 2-hydroxyphenylacetic acid 
by nitration, in the presence of dicyclohexylcarbodiimide 
in dry pyridine [11]. This precursor was reduced by 5% 
palladium on carbon in ethylacetate under hydrogen gas, 
and formylated according to the previous method [11], to 
obtain compound B. The final product was purified by 
silica-gel column chromatography using ethyl acetate/ 
hexane (1:4) as the eluting solvent. The structure was 
characterized by I H-NMR spectra (JEOL GSX-400) and 
elemental analyses for C, H and N, within an error of 
_0.3%. 1H-NMR (CDC13) ~ 3.61 (s, 2H, ArCH2CO), 
6.78-6.83 (m, 2H, ArH), 7.07 (d, J = 7.6 Hz, 1H, CON- 
HCH), 8.03 (dd, J = 2.0, 7.3 Hz, 1H, AsH), 8.19 (br s, 
1H, NHCHO), 8.37 (d, J = 2.1 Hz, 1H, NHCHO), 10.44 
(s, 1H, OH). Anal. Calcd for C29Ha607N2 : C, 65.67; H, 
8.82; N, 5.11. Found: C, 65.47; H, 8.82; N, 4.89. 
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Fig. 1. Structure of the natural antimycin A 3 and synthetic antimycin A analogues studied. The intramolecular hydrogen-bond between the phenolic OH 
and the carbonyl oxygen is represented by a dotted line. 
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Compound D. The precursor of compound D was 
obtained by condensing 2-hydroxy-3-nitrobenzoic ac dwith 
4-(2',6'-di-sec-butylphenoxy)-N-methylaniline in th  pres- 
ence of dicyclohexylcarbodiimide in dry pyridine [11]. The 
compound 4-(2',6'-di-sec-butylphenoxy)-N-methylaniline 
was synthesized by alkaline (K2CO 3) hydrolysis of 4- 
(2',6'-di-sec-butylphenoxy)-N-methyl-N-trifluoroacetylani- 
line, which was prepared from 4-(2',6'-di-sec- 
butylphenoxy)-N-trifluoroacetylaniline by iodomethane 
methylation in the presence of K2CO 3 in dimethylsulf- 
oxide [19]. 4-(2',6'-Di-sec-butylphenoxy)-N-trif luoro- 
acetylaniline was prepared by the reaction of 4-(2',6'-di- 
sec-butylphenoxy)aniline [11] and trifluoroacetic anhydride 
in dichloromethane. To obtain compound D, the above 
precursor was reduced, and formylated as described above. 
1H-NMR (CDCI 3) 6 3.47 (s, 3H, CONCH3), 6.37-6.39 
(m, 1H, ArH), 6.43-6.45 (m, 1H, ArH), 6.72 (d, J = 8.0 
Hz, 1H, ArH), 6.81-6.85 (m, 1H, ArH), 6.98 (s, 1H, 
ArH), 7.00-7.03 (2H, ArH), 7.13 (d, J = 7.6 Hz, 1H, 
ArH), 7.20 (d, J=  6.4 Hz, 1H, ArH), 7.90 (br s, 1H, 
NHCHO), 8.24-8.27 (m, 1H, ArH), 8.46 (d, J = 2.0, 1H, 
NHCHO), 11.90 (s, 1H, OH). Anal. Calcd for 
C29H3404N2: C, 73.39; H, 7.22; N, 5.90. Found: C, 73.20; 
H, 7.22; N, 5.95. The structure was also characterized by 
mass spectra (JEOL JMS-DX300). FAB-MS (m/e) ;  475 
(M++ 1, 70%), 474 (M ÷, 27), 310 (18) and 164 (100). 
Compound E. Compound E was prepared by the 
formylation [11] of the corresponding 3-N-methylamino 
derivative which was obtained by methylation of the corre- 
sponding 3-amino derivative with paraformaldehyde in the 
presence of sodium borohydride in sodium methoxide [20]. 
The synthetic procedures for the 3-amino derivative were 
the same as those for compound C [11]. 1H-NMR (CDC13) 
6 3.26, 3.27 (3H, NCH3), 6.84 (d, J = 8.2 Hz, 2H, ArH), 
6.96-6.98 (3H, ArH), 7.15 (d, J=  7.2 Hz, 1H, ArH), 
7.28-7.33 (m, 1H, ArH), 7.43-7.51 (m, 2H, ArH), 7.52 (t, 
J = 9.5 Hz, 1H, AsH), 7.92, 7.95 (1H, CHO), 8.24 (s, 1H, 
CONH), 12.55 (s, 1H, OH). Anal. Calcd for C29H34OaN2: 
C, 73.39; H, 7.22; N, 5.90. Found: C, 73.15; H, 7.26; N, 
6.15. 
2.3. Methods 
Submitochondrial particles (SMP) were prepared from 
bovine heart mitochondria by the method of Matsuno-Yagi 
and Hatefi [21]. The particles were treated with sodium 
deoxycholate (0.3 mg/mg of protein) before dilution with 
the reaction medium [22]. Cytochrome bcl complex activ- 
ity was measured at 30°C as the rate of cytochrome c 
reduction with DBH as an electron donor. The reaction 
medium consisted of a mixture of 0.25 M sucrose, 1 mM 
MgCI 2, 2 mM KCN, 20 /zM DBH, 20 /xM cytochrome c 
and 50 mM phosphate buffer (pH 7.4), the final mitochon- 
drial protein concentration being 15 /zg/ ml. The molar 
concentration (150) in the incubation medium required to 
halve the control enzyme activity was measured. The 150 
Table 1 
Inhibition of cytochrome bcI complex activity by antimycin A and 
synthetic analogues 
Compounds /5o (nM) OH signal, 6 (ppm) a 
A 4.5 12.93 
B 47800 10.44 
C 2.8 12.89 
D 2700 11.90 
E 460 12.60 
Antimycin Ab 2.4 12.57 c 
a 1H_NM R (400 MHz) chemical shift (ppm) of the phenolic OH proton. 
b Antimycin m 3 was used. 
c From Ref. 24. 
value was the average of the values of three series mea- 
surements. 
The stable conformation of 3-formylamino group was 
studied by molecular orbital methods. Computations were 
achieved by use of AMPAC (QCPE No. 523) with AM1 
parameterization [23]. Initial conformations were con- 
structed using standard bond lengths and angles. The tor- 
sion angle of the amide bond was set at 180 ° in the initial 
conformation. 
3. Results 
3.1. The role of the amide bond bridge in the inhibitory 
action 
The 400 MHz 1H-NMR spectra showed a remarkable 
difference in the phenolic OH proton signals between 
compounds A and B. Signals of the OH proton of the 
former and latter compounds appeared at 12.93 and 10.44 
ppm, respectively, in chloroform-d I at 25°C (Table 1). 
Judging from the downfield-shifled signal of the phenolic 
OH proton of compound A, this OH group should form an 
intramolecular hydrogen-bond. Since such a remarkable 
downfield-shift signal was not observed with compound B, 
it is reasonable to consider that a six-membered hydrogen- 
bonded ring is formed between the phenolic OH and the 
carbonyl groups in the 1-position. On the other hand, since 
the signal for the phenolic OH proton of natural antimycin 
A appears at 12.57 ppm [17,24]; this kind of intramolec- 
ular hydrogen-bond is also formed with natural antimycin 
A. 
Thus, to examine whether the formation of the intra- 
molecular hydrogen-bond is important for the inhibitory 
action of antimycin A, we compared the inhibitory activi- 
ties between compounds A and B. The inhibition of cy- 
tochrome bc I complex activity by compounds A and B 
was examined with bovine heart submitochondrial parti- 
cles. As shown in Table 1, the inhibitory potency of 
compound B was about 10000-times less than that of 
compound A. This indicated that the formation of an 
intramolecular hydrogen-bond is essential for the in- 
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hibitory action. This idea is supported by the previous 
observation that replacing the phenolic OH by methoxy 
group resulted in a large loss of inhibitory potency [13]. 
It is unclear whether the formation of the intramolecular 
hydrogen-bond is important for occupying the antimycin 
binding site or for inhibiting the catalytic reaction at the Qi 
center. To see whether compound B can occupy the bind- 
ing site without inhibiting the catalytic reaction, we mea- 
sured the inhibition by antimycin A or compound A using 
submitochondrial particles treated with at least about 
1000-fold excess of compound B (7.6 /zM). Compound B
alone at this concentration did not inhibit control enzyme 
activity. The inhibitory potencies of antimycin A and 
compound A were not affected in the presence of excess 
compound B (data not shown), indicating that compound B
can not replace these inhibitors from their binding site. It is 
therefore concluded that the formation of an intramolecular 
hydrogen-bond is important for inhibitor fitting to the 
binding site. 
Next we examined the effect of N-methylation of the 
amide bond on the activity. Since the synthesis of a 
N-methyl derivative corresponding to compound A was 
unsuccessful, that corresponding to compound C was syn- 
thesized. Signals for the phenolic OH proton of com- 
pounds C and D appeared at 12.86 and 11.90 ppm, respec- 
tively. This means that the intramolecular hydrogen-bond 
of interest is somewhat disturbed for compound D by 
steric congestion due to N-methylation, whereas a weak 
intramolecular hydrogen bond is still formed. The in- 
hibitory potency of compound D was about 1000-fold less 
than that of compound C. Although some decrease in the 
inhibitory potency was predicted from the weakness of the 
intramolecular hydrogen-bond formation, this large loss of 
activity might be not accounted for solely from the weak- 
ness in the intramolecular hydrogen-bond. We therefore 
suggest hat the amide NH group takes part in hydrogen- 
bond interaction with the binding site, functioning as a 
hydrogen-bond donor. 
Compounds A and C elicit the same effects as natural 
antimycin A on the reduction of cytochrome b; that is, an 
extra reduction of cytochrome b reduced by substrate, 
oxidant-induced reduction and a blockage of cytochrome b 
reduction in combination with myxothiazol (under "double 
kill" conditions) [11,13]. The investigations with com- 
pounds B and D were however, experimentally impractical 
because of the limited solubility of these compounds in the 
effective concentration range under the experimental con- 
ditions (2 /zM cytochrome bc l complex). 
3.2. The role of the 3-formylamino group in the inhibitory 
action 
To examine the role of NH of the 3-formylamino group 
in the activity, we synthesized compound E. The activity 
of this compound was significantly decreased compared 
with that of compound C (Table 1). The iH-NMR spectra 
of compound E in chloroform-d t at 25 ° C revealed signals 
at 7.93 and 7.97 ppm, assigned to the formyl proton, and at 
3.26 and 3.27 ppm, assigned to the N-methyl protons, in a 
ratio of 4:5, respectively. This indicated that the 3-formyl 
A H~_ ~0 IH. ,  
01 0 "0 
5 
B H~ ~,~0 ~H, 
o~ vi~ 0 "'0 
Me" " ~" 
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180 360 
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Fig. 2. Conformational energy diagrams of 3-formylamino-2-hydroxy N-methylbenzamide (A) and 3-formylamino-2-hydroxy-4-methyl N-methylbe- 
nzamide (B). The 3-formylamino group was rotated along 01 and 02 in steps of 20 ° . The contours represent 1, 2, 3, 4, 6, 8, 10, 12 or 14 kcal tool- i 
above the global minimum for each molecule. The inside of the shaded region is 2 kcal tool- 1 or less in energy above the global minimum. 
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H 
Fig. 3, A possible active conformation of 3-formylamino group. This 
corresponds to the most stable conformation shown in Fig, 2 (01 = 0 ° 
and 02 = 180 ° ). 
N-methylamino group of compound E takes two stable 
conformations, due to a restriction in the rotational motion 
around OHC-NMe bond. Therefore, a decrease in the 
activity of compound E might be due to a difficulty in 
taking an active conformation owing to a loss of flexibil- 
ity. This result seems to be consistent with previous obser- 
vations [13] that the 3-formylamino group takes two stable 
conformations in the presence of a methyl group at the 
4-position (but not at 5-position), and that the activity of 
3-formylamino-4-methyl derivative is significantly less 
than that of 3-formylamino derivative. 
It was thus suggested that the 3-formylamino group has 
to be flexible to take a particular active conformation i
the binding cavity. To obtain information on the active 
conformation of the 3-formylamino group, conformational 
energy studies were performed using 3-formylamino-2-hy- 
droxy N-methylbenzamide (Fig. 2A) and 3-formylamino- 
2-hydroxy-4-methyl N-methylbenzamide (Fig. 2B) as 
model compounds. The latter was chosen to determine the 
effect of steric congestion around the 3-formylamino group 
on the conformation. 
The 3-formylamino group was rotated along 0 t and 02 
(Fig. 2) in steps of 20 ° and the total energy of the 
molecule was calculated for each conformation. The con- 
formation of the phenolic OH and amide bond moiety was 
optimized to form an intramolecular hydrogen-bond be- 
tween the phenolic OH and the carbonyl oxygen. The 
lowest energy conformation of 3-formylamino-2-hydroxy 
N-methylbenzamide and 3-formylamino-2-hydroxy-4- 
methyl N-methylbenzamide was found at about 01 = 0 °, 
02 = 180 ° and 01 = 180 °, 02 --- 340 °, respectively. The 
shaded regions represent 2 kcal mol 1 or less in energy 
above the global minimum. We assumed that the confor- 
mation of 3-formylamino group, which is stable in the 
absence, and destabilized by introduction of a 4-methyl 
group, is a candidate for the active conformation. From 
Fig. 2, it is clear that the total energy of the conformation 
(01 = 0 ° , 02 = 180 ° ) is increased by steric repulsion aris- 
ing from the vicinal (4-position) methyl group. It is there- 
fore likely that the structure, shown in Fig. 3, is a reason- 
able model for the active conformation of the 3-for- 
mylamino group. 
4. Discussion 
The present study demonstrated that (1) the formation 
of a six-membered intramolecular hydrogen-bond between 
the phenolic OH and the amide carbonyl is essential for 
the inhibitory action; (2) a free NH of the amide bond 
bridge is important for supporting the formation of the 
intramolecular hydrogen-bond and also for functioning as 
a hydrogen-bond donor and (3) the conformation of 3-for- 
mylamino group, in which the carbonyl oxygen projects to 
the opposite side of the phenolic OH group, might be a 
good model of the active conformation. Based upon the 
information obtained from a series of structure-activity 
studies of synthetic antimycin A analogues [10,11,13] and 
here, we proposed a tentative model for antimycin A 
binding in its binding cavity (Fig. 4). Since details of 
three-dimensional structure of the Qi reaction center are 
still vague, although models for topological organization of 
cytochrome b have been proposed [4,25-27], the informa- 
tion obtained from the structure-inhibitory activity studies 
of antimycin A analogues should be helpful at the present 
time to predict he interaction between antimycin A and its 
binding site. 
The configuration of whole antimycin A molecule is 
very important for inhibitor binding to the cavity [10]. It is 
notable that the aromatic and dilactone ring planes locate 
H-bond site 
j ~  nonessential for activity 
steric restriction H 0 0 
. . . . . . . . . . .  
.............. OCO 
H-bond site H-bend ?i: ~ [,~drophobic nteraction 
' -  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Fig. 4. A tentative model for antimycin A binding in its binding cavity. The aromatic and dilactone-ring planes locate on and above that of the page, 
respectively. The dotted lines represent hydrogen-bonded bridges. 
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on and above the page plane in Fig. 4, respectively. Since 
the natural dilactone ring is not essential for the activity 
[11], this moiety may regulate the tight fitting of the 
salicylic acid moiety into the cavity by fixing the whole 
molecular configuration and enhancing the hydrophobicity 
of the molecule. A six-membered hydrogen-bond between 
the phenolic OH and carbonyl group makes the amide 
bond plane coplanar to that of aromatic ring. Considering 
the remarkable loss of the inhibitory potency by the lack of 
the hydrogen-bond, both the phenolic OH and carbonyl 
groups may form hydrogen-bond bridges in such a f i xed  
conformation to some residues in the binding site, although 
the residues remains to be determined. One may not rule 
out the possibility that the fixed conformation itself of 
antimycin A is required for tight binding to its binding site. 
On the other hand, a large loss of the activity by N-meth- 
ylation suggests that the amide NH forms a hydrogen-bond 
to the binding site. 
A previous report [13] and this study indicate that when 
the rotational freedom of 3-formylamino group is reduced 
by steric congestion, the activity significantly decreases, 
probably due to the difficulties involved in taking an active 
conformation. Considering this and the molecular orbital 
calculations performed here, an active conformation of the 
3-formylamino group might be obtained when the formyl 
carbonyl group projects to the opposite side of the pheno- 
lic OH group. With respect o the effect of N-methylation 
of 3-formylamino group, the possibility that the lack of 
hydrogen-bond formation is responsible for a decrease in 
the activity would be not excluded. It is, however, reason- 
able to assume that the contribution of the NH group to the 
activity as a hydrogen-bond donor is, if there is any at all, 
not so important, since the degree of a decrease in the 
activity by N-methylation is much less than that which was 
observed when the hydrogen-bond was lost (compounds A 
vs. B and compounds C vs. D). On the other hand, it has 
been shown that the bulkier the portion corresponding to 
the formyl proton (shadowed in Fig. 4) of the 3-for- 
mylamino group, the lower was the activity [13]. Taking 
these facts into account, the presence of the 3-formylamino 
group itself in its proper conformation is essential for tight 
binding. In other words, this functional group is strictly 
recognized by the binding cavity. There may be a hydro- 
gen-bond between the carbonyl oxygen of 3-formylamino 
group and the binding site. 
Novel antimycin derivatives have the important poten- 
tial of better defining how the inhibitor is bound to cy- 
tochrome b, when the mutational analysis of resistance to 
these compounds is carried out. The inhibition test of a 
series of synthetic antimycin A derivatives using an- 
timycin-resistant mitochondrial mutants from yeast [4,25] 
and mouse [9] is currently in progress. 
Acknowledgements 
We thank Dr. Yuji Nakamura, Central Research Insti- 
tute, lshihara Sangyo Kaisha Ltd., (Japan) for facilitating 
the use of NMR spectrometer (JEOL GSX-400). 
References 
[1] Trumpower, B.L. (1990)J. Biol. Chem. 265, 11409-11412. 
[2] Kr6ger, A and Klingenberg, M. (1973) Eur. J. Biochem. 39, 313- 
323. 
[3] Von Jagow, G. and Link, T.A. (1986) Methods Enzymol. 126, 
253-271. 
[4] Di Rago, J.P. and Colson, A.M. (1988) J. Biol. Chem. 263, 12564- 
12570. 
[5] Nieboer, P. and Berden, J.A. (1992) Biochim. Biophys. Acta 1101, 
90-96. 
[6] Bechmann, G., Weiss, H. and Rich, P. (1992) Eur. J. Biochem. 208, 
315-325. 
[7] Weber, S. and Wolf, K. (1986) FEBS Lett. 237, 31-34. 
[8] Di Rago, J.P., Netter, P. and Slonimski, P.P. (1990) J. Biol. Chem. 
265, 15750-15757. 
[9] Howell, N. (1990) Biochemistry 29, 8970-8977. 
[10] Miyoshi, H., Kondo, H., Oritani, T., Saitoh, I. and lwamura, H. 
(1991) FEBS Lett. 292, 62-63. 
[11] Tokutake, N., Miyoshi, H., Nakazato, H. and lwamura, H. (1993) 
Biochim. Biophys. Acta 1142, 262-268. 
[12] Copp6e, J.Y., Tokutake, N., Marc, D., Di Rago, J.P., Miyoshi, H. 
and Colson, A.M. (1994) FEBS Lett. 339, 1-6. 
[13] Tokutake, N., Miyoshi, H., Satoh, I., Hatano, T. and lwamura, H. 
(1994) Biochim. Biophys. Acta 1185, 271-278. 
[14] Rieske, J.S. (1980) Pharmacol. Ther. 11,425-450. 
[15] Wilson, E., Farley, T.M. and Takemoto, J.Y. (1985) J. Biol. Chem. 
260, 10288-10292. 
[16] Wasserman, H.H. and Gambale, R.J. (1985) J. Am. Chem. Soc. 107, 
1423-1424. 
[17] Wasserman, H.H. and Gambale, R.J. (1992) Tetrahedron 48, 7059- 
7070. 
[18] Saitoh, I., Miyoshi, H., Shimizu, R. and Iwamura, H. (1992) Eur. J. 
Biochem. 209, 73-79. 
[19] Jonstone, R.A.W., Payling, D.W. and Thomas, C. (1969) J. Chem. 
Soc. (C) 2223-2224. 
[20] Barluenga, J. Bay6n, A.M. and Asensio, G. (1984) J. Chem. Soc., 
Chem. Commun. 1334-1335. 
[21] Matsuno-Yagi, A. and Hatefi, Y. (1985) J. Biol. Chem. 260, 14424- 
14427. 
[22] Esposti, M.D. and Lenaz, G. (1982) Biochim. Biophys. Acta 682, 
189-200. 
[23] Dewar, M.J.S., Zoebisch, E.G., Healy, E.F. and Stewart, J.J.P. 
(1985) J. Am. Chem. Soc. 107, 3902-3909. 
[24] Kinoshita, M., Aburaki, S., Wada, M. and Umezawa, S.(1973) Bull. 
Chem. Soc. Jpn. 46, 1279-1287. 
[25] Copp6e, J.Y., Brasseur, G., Brivet-Chevillotte, P. and Colson, A.M. 
(1994) J. Biol. Chem. 269, 4221-4226. 
[26] Robertson, D.E., Daldal, F. and Dutton, P.L. (1990) Biochemistry 
29, 11249-11260. 
[27] Link, T.A., Wallmeier, H. and Von Jagow, G. (1994) Biochem. Soc. 
Trans. 22, 197-203. 
